Loading organizations...
§ Venture Capital · Brisbane, Australia
Venture capital firm investing in and building early-stage oncology companies, focused on cancer therapeutics.
Aglaia BioMedical Ventures is a venture capital firm based in Bilthoven, Netherlands, that invests exclusively in early-stage oncology therapeutics and medical diagnostics companies. The organization provides strategic capital and operational support to mature scientific inventions from early research phases through clinical development, preparing them for licensing, acquisitions, or initial public offerings. Operating across multiple investment vehicles, the firm manages over €130 million in total assets under management, which includes its €85 million Aglaia Oncology Fund III. The firm has historically invested in or incubated 12 biomedical startups, successfully advancing six of these ventures into clinical testing stages. Its investment portfolio features notable biotechnology companies such as Merus, Inthera Bioscience, BioInvent, and OcellO, which was acquired by Crown Bioscience in 2021. Aglaia BioMedical Ventures was founded in 2003 by Karl Rothweiler, Mark Krul, and Paul Cleophas.
Aglaia BioMedical Ventures has raised $4.7M across 1 funding round.
Key people at Aglaia BioMedical Ventures.
Aglaia BioMedical Ventures has raised $4.7M in total across 1 funding round.
Aglaia BioMedical Ventures has raised $4.7M in total across 1 funding round.
Aglaia BioMedical Ventures's investors include Alejo Chorny, Credit Mutuel Innovation, Pierre Fabre Invest.
Key people at Aglaia BioMedical Ventures.
Aglaia BioMedical Ventures has raised $4.7M across 1 funding round. Most recently, it raised $4.7M Aglaia Oncology Funds - Seed in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 27, 2021 | $4.7M Seed | Alejo Chorny | Credit Mutuel Innovation, Pierre Fabre Invest | Announced |
Aglaia BioMedical Ventures is a Netherlands-based private equity and venture capital firm founded in 2003 that specializes in early-stage investments in the life sciences sector, particularly oncology drug development and biomedical innovations[1][2]. Their mission centers on advancing breakthrough cancer treatments by selecting and nurturing early-stage biotech companies with transformative potential. Aglaia combines strategic investment with hands-on operational support to mature startups from incubation through clinical stages, aiming to create impactful medicines for cancer patients while delivering strong financial returns[2]. Their investment philosophy emphasizes close collaboration with innovators, leveraging decades of oncology expertise to de-risk and accelerate portfolio companies. Aglaia’s impact extends beyond capital, contributing to the startup ecosystem by fostering innovation in oncology and life sciences, and by developing tools to measure socio-economic impact in biotech[2].
Aglaia BioMedical Ventures was founded in 2003 in Bilthoven, the Netherlands, by a team with deep experience in cancer research and drug development[1][2]. The firm evolved with a clear focus on oncology, building a reputation for launching and supporting biotech startups that develop novel cancer therapies. Over time, Aglaia has expanded its approach to include incubation, early-stage financing, PIPEs, and bridge financing, reflecting a comprehensive lifecycle investment strategy[1]. The founding team’s scientific and operational expertise has been pivotal in shaping the firm’s hands-on involvement in portfolio companies, guiding them through critical R&D phases and clinical development[2].
Aglaia rides the global trend of precision oncology and biotech innovation, where breakthroughs in cancer biology and drug development are rapidly transforming treatment paradigms. The timing is critical as advances in molecular biology, immunotherapy, and personalized medicine create fertile ground for early-stage biotech ventures. Market forces such as increasing cancer incidence, demand for novel therapies, and growing investor interest in life sciences underpin Aglaia’s focus. By de-risking early-stage oncology companies and guiding them to clinical validation, Aglaia influences the broader ecosystem by enabling the translation of scientific discoveries into viable therapies, thus accelerating innovation cycles and attracting further investment into the sector[2].
Looking ahead, Aglaia BioMedical Ventures is well-positioned to capitalize on emerging oncology trends such as cell and gene therapies, AI-driven drug discovery, and biomarker-driven clinical trials. Their hands-on, science-driven investment approach will likely continue to yield high-impact startups that can progress to licensing deals, acquisitions, or IPOs. As the biotech ecosystem grows more competitive and complex, Aglaia’s operational expertise and impact measurement tools may become even more valuable differentiators. Their influence is expected to expand as they help shape the next generation of cancer therapeutics, reinforcing their dual mission of societal benefit and financial success[2]. This trajectory ties back to their foundational vision of transforming stellar science into life-saving medicines.
